Drug-induced gastric ulcers are caused by more than just NSAIDs: Alendronate gastric ulcers

Graham, D.Y.; Malaty, H.M.

doi:10.1016/s0016-5085(98)80561-1

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports have implicated alendronate as a cause of esophageal and gastric mucosal damage (7)(8)(9)(10). In this study, no esophageal injury could be detected.…”

Section: Discussionsupporting

confidence: 42%

“…Some studies have tempered the enthusiasm for this agent, suggesting that it may have serious predictable toxicity in the upper gastrointestinal tract (7)(8)(9)(10).…”

Section: Discussionmentioning

confidence: 99%

“…Graham et al reported that 58% of volunteers (young men and women) given alendronate for 4 days at high dose (40 mg/day) developed gastric injury (9). In a similar study using 10 mg for 14 days, alendronate reportedly caused visible gastric mucosal injury in 47%, and three of 15 volunteers developed gastric ulcers (10). These findings are not supported, however, by another study that suggests that 10 mg/day does not have any toxic effect on the gastric mucosa (11).…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Upper gastrointestinal toxicity of alendronate

Lowe¹,

Depew²,

Vanner³

et al. 2000

Am J Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Previous reports have implicated alendronate as a cause of esophageal and gastric mucosal damage (7)(8)(9)(10). In this study, no esophageal injury could be detected.…”

Section: Discussionsupporting

confidence: 42%

“…Some studies have tempered the enthusiasm for this agent, suggesting that it may have serious predictable toxicity in the upper gastrointestinal tract (7)(8)(9)(10).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Upper gastrointestinal toxicity of alendronate

Lowe¹,

Depew²,

Vanner³

et al. 2000

Am J Gastroenterology

View full text Add to dashboard Cite

show abstract

“…There was no correlation in this study between the occurrence of upper gastrointestinal adverse events and maximum EGD scores in the risedronate 5 mg group. A lack of correlation between the presence of gastric ulcers and upper gastrointestinal symptoms was previously noted in an endoscopic study of alendronate 32 . Indeed, there is a frequent dissociation between peptic ulcers and symptoms, and most patients who die from ulcer complications have no symptoms to warn them of the severity of their condition 33 .…”

Section: Discussionmentioning

confidence: 96%

Placebo‐controlled, randomized, evaluator‐blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women

Lanza¹,

Rack²,

Li³

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Bisphosphonates are effective treatments for osteoporosis. Since some primary amino bisphosphonates are associated with oesophageal injury, we conducted a study of the upper gastrointestinal effects of risedronate, a pyridinyl bisphosphonate. Methods: Healthy, postmenopausal women received risedronate 5 mg (n=26), aspirin 2600 mg (n=27), or placebo (n=27) daily for 14 days and underwent endoscopy at baseline, Day 8 and Day 15. Results: Oesophageal erosions were noted in one subject in the aspirin group, two in the placebo group, and none in the risedronate group, and an ulcer in one aspirin‐treated subject. Gastric erosions and ulcers were observed most frequently in the aspirin group. Gastric ulcers were noted in eight subjects in the aspirin group, one in the placebo group, and none in the risedronate group (P=0.010, placebo vs. aspirin; P=0.002, risedronate vs. aspirin). Duodenal erosions and ulcers were observed in the aspirin group only. Gastroduodenal erosion scores of three or more occurred more frequently in the aspirin than in the risedronate and placebo groups (P < 0.001). Conclusions: Risedronate 5 mg was not associated with oesophageal or gastroduodenal ulcers in healthy, postmenopausal women, a population representative of patients who will receive risedronate in the clinical setting.

show abstract

“…There have been several reports of adverse gastrointestinal events associated with some N‐BPs (e.g. Fosamax, Aredia), including nausea, vomiting, pain, diarrhoea and ulceration of the stomach and oesophagus 2 –9 . A study of the possible causative mechanisms behind the damage seen during N‐BP treatment is needed for the development of dosing regimens that avoid inducing such injury.…”

Section: Introductionmentioning

confidence: 99%

Gastric damage in the rat with nitrogen‐containing bisphosphonates depends on pH

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Drug-induced gastric ulcers are caused by more than just NSAIDs: Alendronate gastric ulcers

Cited by 5 publications

References 0 publications

Upper gastrointestinal toxicity of alendronate

Upper gastrointestinal toxicity of alendronate

Placebo‐controlled, randomized, evaluator‐blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women

Gastric damage in the rat with nitrogen‐containing bisphosphonates depends on pH

Contact Info

Product

Resources

About